Thermo Fisher ends deal agreement for genetic testing firm Qiagen

(Reuters) – Thermo Fisher Scientific said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen as the minimum acceptance threshold to its tender offer were not met.

Thermo Fisher’s revised offer had valued Qiagen at 11.3 billion euros ($13.38 billion).

Qiagen’s shares fell 1.5% in premarket trading after the announcement.

($1 = 0.8445 euros)

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)